Corbus Pharmaceuticals Holdings (CRBP) Non-Current Assets (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Non-Current Assets of $1.2 million for Q4 2025, down 57.25% year-over-year from $2.9 million in Q4 2024, and down 36.13% quarter-over-quarter from $1.9 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Non-Current Assets (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non-Current Assets history runs 12 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 57.25% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $8.0 million (down 42.34% YoY), while the FY2025 annual figure was $1.2 million, down 57.25% from the prior year.
- Non-Current Assets for Q4 2025 stood at $1.2 million, down from $1.9 million in the prior quarter.
- The five-year high for Non-Current Assets was $9.9 million in Q1 2021, with the low at $1.2 million in Q4 2025.
- The 5-year median for Non-Current Assets is $5.3 million (2023), against an average of $5.2 million.
- The sharpest annual moves came in 2021 and 2025: Non-Current Assets retreated 6.53% in 2021, then sank 57.25% in 2025.
- Corbus Pharmaceuticals Holdings' Non-Current Assets stood at $7.5 million in 2021, then declined by 18.53% to $6.1 million in 2022, then decreased by 22.91% to $4.7 million in 2023, then sank by 38.57% to $2.9 million in 2024, then sank by 57.25% to $1.2 million in 2025.
- Business Quant data shows CRBP's Non-Current Assets at $1.2 million in Q4 2025, $1.9 million in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 3.28 Mn |
| Jun 30, 2024 | 3.67 Mn |
| Mar 31, 2024 | 4.05 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Sep 30, 2023 | 5.08 Mn |
| Jun 30, 2023 | 5.45 Mn |
| Mar 31, 2023 | 5.78 Mn |
| Dec 31, 2022 | 6.13 Mn |
| Sep 30, 2022 | 6.48 Mn |
| Jun 30, 2022 | 6.83 Mn |
| Mar 31, 2022 | 7.20 Mn |
| Dec 31, 2021 | 7.53 Mn |
| Sep 30, 2021 | 7.91 Mn |
| Jun 30, 2021 | 9.03 Mn |
| Mar 31, 2021 | 9.86 Mn |